Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus rating of “Buy” by the twelve analysts that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $20.78.
A number of research analysts have recently commented on INO shares. Stifel Nicolaus reissued a “buy” rating and set a $11.00 target price on shares of Inovio Pharmaceuticals in a research report on Thursday, May 25th. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a research report on Tuesday, July 11th. Maxim Group set a $12.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, June 8th. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Inovio Pharmaceuticals in a research report on Friday, June 9th. Finally, ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd.
ILLEGAL ACTIVITY WARNING: “Inovio Pharmaceuticals, Inc. (INO) Given Average Recommendation of “Buy” by Analysts” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://stocknewstimes.com/2017/09/13/inovio-pharmaceuticals-inc-ino-given-average-recommendation-of-buy-by-analysts.html.
A number of institutional investors have recently added to or reduced their stakes in the company. Wasatch Advisors Inc. increased its position in shares of Inovio Pharmaceuticals by 43.6% in the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock valued at $20,469,000 after buying an additional 793,306 shares during the period. Vanguard Group Inc. increased its stake in shares of Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock valued at $20,510,000 after buying an additional 226,861 shares during the last quarter. Candriam Luxembourg S.C.A. bought a new stake in shares of Inovio Pharmaceuticals during the second quarter valued at about $1,411,000. GSA Capital Partners LLP bought a new stake in shares of Inovio Pharmaceuticals during the second quarter valued at about $1,035,000. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Inovio Pharmaceuticals during the second quarter valued at about $556,000. Hedge funds and other institutional investors own 24.83% of the company’s stock.
Inovio Pharmaceuticals (NASDAQ INO) traded up 3.84% during mid-day trading on Tuesday, hitting $5.95. 1,375,742 shares of the stock traded hands. The stock’s market cap is $536.85 million. The stock has a 50-day moving average price of $6.15 and a 200-day moving average price of $6.75. Inovio Pharmaceuticals has a 12 month low of $5.28 and a 12 month high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The business had revenue of $20.41 million for the quarter, compared to analysts’ expectations of $16.29 million. During the same period in the previous year, the company posted ($0.26) earnings per share. The business’s revenue for the quarter was up 229.2% compared to the same quarter last year. On average, equities analysts forecast that Inovio Pharmaceuticals will post ($0.92) earnings per share for the current year.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.